Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study

Lee, Soon Kyu; Lee, Sung Won; Lee, Hae Lim; Kim, Hee Yeon; Kim, Chang Wook; Song, Do Seon; Chang, U Im; Yang, Jin Mo; Yoo, Sun Hong; Kwon, Jung Hyun; Nam, Soon Woo; Kim, Seok Hwan; Song, Myeong Jun; Lee, Jaejun; Yang, Hyun; Bae, Si Hyun; Han, Ji Won; Nam, Heechul; Sung, Pil Soo; Jang, Jeong Won; Choi, Jong Young; Yoon, Seung Kew

doi:10.3904/kjim.2022.013

Cited by 3 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein kinase A Peptide receptor swCNT [44] FET I ds -Time 1.2 mU/mL Peptide receptor AuNP/reduced graphene oxide [45] Electrochemistry Electrochemical impedance spectroscopy 53 mU/mL Glutamate Enzyme swCNT [46] FET I ds -Time 92 pM Enzyme PtDENs/swCNT [47] Electrochemistry Amperometric i-t curve 6.64 μM…”

Section: L-cysteinementioning

confidence: 99%

Fabrication and Functionalisation of Nanocarbon‐Based Field‐Effect Transistor Biosensors

et al. 2022

View full text Add to dashboard Cite

Nanocarbon-based field-effect transistor (NC-FET) biosensors are at the forefront of future diagnostic technology. By integrating biological molecules with electrically conducting carbon-based platforms, high sensitivity real-time multiplexed sensing is possible. Combined with their small footprint, portability, ease of use, and label-free sensing mechanisms, NC-FETs are prime candidates for the rapidly expanding areas of point-of-care testing, environmental monitoring and biosensing as a whole. In this review we provide an overview of the basic operational mechanisms behind NC-FETs, synthesis and fabrication of FET devices, and developments in functionalisation strategies for biosensing applications.

show abstract

Section: L-cysteinementioning

confidence: 99%

Fabrication and Functionalisation of Nanocarbon‐Based Field‐Effect Transistor Biosensors

et al. 2022

View full text Add to dashboard Cite

show abstract

Ledipasvir/sofosbuvir

2023

Reactions Weekly

View full text Add to dashboard Cite

Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years

Park,

Na,

Yoon

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Chronic hepatitis C (CHC) can be cured with direct-acting antiviral (DAA) therapy. In Korea, sofosbuvir (SOF) and ledipasvir (LDV)/SOF were launched in 2016. Patients who achieve a sustained virologic response (SVR) following DAA treatment are predicted to have a favorable prognosis. Nevertheless, little is known regarding the prognosis of Korean CHC patients who receive SOF-based treatment and achieve SVR. Therefore, the purpose of this study was to look into the long-term outcomes for these patients. Materials and Methods: This was a prospective, multicenter observational study. CHC patients were enrolled who, following SOF or LDV/SOF treatment, had achieved SVR. The last day for follow-up was December 2023. The primary endpoint was HCC occurrence, which was checked at least once per year. Results: A total of 516 patients were included in this analysis, with a median follow-up duration of 39.0 months. Among them, 231 were male patients (44.8%), with a median age of 62.0 years. Genotypes were 1 (90, 17.4%), 2 (423, 82.0%), and 3 (3, 0.6%). The combination of SOF plus ribavirin was the most common treatment (394, 76.4%). In total, 160 patients were cirrhotic (31.0%), and the mean Child–Pugh score was 5.1. Within a maximum of 7 years, 21 patients (4.1%) developed HCC. Patients with HCC were older (69 vs. 61 years, p = 0.013) and had a higher cirrhosis incidence (81.0 vs. 28.9%, p < 0.001), higher AFP (6.0 vs. 3.3, p = 0.003) and higher APRI (0.8 vs. 0.5, p = 0.005). Age over 65 (p = 0.016) and cirrhosis (p = 0.005) were found to be significant risk factors for HCC by Cox regression analysis. Conclusions: Patients who achieved SVR with SOF-based treatment had a relatively favorable prognosis. However, the risk of HCC was not eliminated, especially in older and cirrhotic patients. Therefore, routine follow-up, surveillance, and early treatment are required.

show abstract

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study

Cited by 3 publications

References 38 publications

Fabrication and Functionalisation of Nanocarbon‐Based Field‐Effect Transistor Biosensors

Fabrication and Functionalisation of Nanocarbon‐Based Field‐Effect Transistor Biosensors

Ledipasvir/sofosbuvir

Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years

Contact Info

Product

Resources

About